Teva Pharmaceuticals Acquires BioXcel Therapeutics Neuroscience Assets in Bankruptcy Proceedings
Teva Pharmaceuticals completed its acquisition of worldwide rights to dexmedetomidine sublingual film from BioXcel Therapeutics on October 27, according to an announcement from law firm Ropes & Gray. The transaction, executed through BioXcel’s Chapter 11 bankruptcy proceedings, centers on an orally dissolving formulation currently under review by the U.S. Food and Drug Administration for at-home acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Financial Terms and Contingent Payments Tied to FDA Approval
Under the purchase agreement, Teva paid an upfront amount of $57.5 million to secure the neuroscience assets. The deal includes up to an additional $67.5 million in contingent payments tied directly to future FDA approval timing and specific sales milestones. The acquired portfolio features IGALMI (dexmedetomidine sublingual film), which already holds FDA approval for the in-clinic acute treatment of agitation tied to schizophrenia and bipolar disorders, alongside the developmental candidate BXCL501.
$BTAI files for bankruptcy.Asset sale agreement with $TEVA https://t.co/Bxdn7dWA98
Regulatory Status of BXCL501 for At-Home Treatment
The asset includes BXCL501. If the FDA grants approval for at-home use, the formulation will become the first federally approved oral treatment of its kind for managing acute agitation outside of a clinical setting. The regulatory review process governs the timeline for the remaining contingent financial milestones outlined in the transaction agreements.
Legal and Advisory Representation
The Ropes & Gray legal team advised Teva Pharmaceuticals throughout the bankruptcy and asset purchase process. Mergers and acquisitions counsel Kelly Finn and partner Chris Comeau led the transaction, working alongside life sciences licensing partner Abby Gregor, business restructuring partners Rachel Strickland and Andrew Mordkoff, and health care partner Jamie Darch.
Frequently Asked Questions
What specific assets did Teva Pharmaceuticals acquire from BioXcel Therapeutics?
Teva acquired worldwide rights to dexmedetomidine sublingual film, which includes the currently approved in-clinic treatment IGALMI and the developmental at-home candidate BXCL501, out of BioXcel’s Chapter 11 bankruptcy proceedings.
How much did the acquisition cost upfront?
Teva paid an upfront amount of $57.5 million, with an additional $67.5 million in contingent payments tied to sales milestones and FDA approval timing.
What condition is dexmedetomidine sublingual film intended to treat?
The sublingual film treats acute agitation associated with schizophrenia or bipolar I or II disorder in adults, with the new formulation specifically seeking approval for at-home administration.
Keep reading